Skip to main content

Tweets

Should we be using JAKi more in female SpA patients? In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
💬 #ACR25 Topic Panels — LIVE! Nov. 4 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: CAR-T Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/zedho2RI6T
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults In RA alone, nearly 40% of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental https://t.co/2pqXGURQtL
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
Tofacitinib in AxSpA in Developing Countries Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25 https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the https://t.co/DBoteUTavZ
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 primary outcome at wk 52. The anti-CD20, B-cell depleter, Rx met all efficacy endpoints primary and all key secondary endpoints. Gazyva was FDA approved last wk https://t.co/Wd6EFEjvGP
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
Difficult to Manage axSpA Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns", presented at #ACR25 https://t.co/84HZojI3FJ
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
FDA is going to "fast-track" biosimilars to curtail the costs of expensive biologics https://t.co/h5NBsUaM97

Dr. John Cush @RheumNow ( View Tweet )

2 months 1 week ago
Not only lovely work @TheLancetRheum from @jeffsparks and friends, but they have some AI imaging work up tomorrow from the same SAIL-RA cohort, showing the spectrum of impact in all RA patients, using radiomics. Check it out #ACR25 ABST1751 @RheumNow https://t.co/TlmHOOpNNp https://t.co/P62RXI8ePQ

David Liew @drdavidliew ( View Tweet )

2 months 1 week ago
A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH. What is the most likely diagnosis? https://t.co/afPUeaqfZT
Dr. Nikhil Agrawal @DrNikhilMD ( View Tweet )
2 months 1 week ago
If you missed this pattern, you missed an autoimmune classic What’s it? https://t.co/zO48zPCkqP
2 months 1 week ago
#ACR25 Abstract 1526 “Guidance for #Steroid Tapering in Systemic Lupus Erythematosus” 101 international experts reached Delphi consensus on CS tapering strategies in #SLE. 🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement. https://t.co/GRlUz3Y3EP
2 months 1 week ago
×